"Combination Immunotherapy, Chemotherapy Feasible In Metastatic Bladder Cancer" - Andy Polhamus
Combination therapy with immune checkpoint blockade and chemotherapy appeared feasible for some patients with metastatic bladder cancer, study data showed. “Because chemotherapy and immunotherapy are the two pillars of treatment for metastatic bladder cancer, we sought to better understand how these treatments might be best given together,” said Matthew Galsky, MD, director of the novel therapeutics program and genitourinary medical oncology at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “Already the results of this trial have inspired the creation of two more trials that seek to better the treatment of patients with bladder cancer by combining chemotherapy with immunotherapy.”
- Matthew Galsky, MD, Director, The Novel Therapeutics Program, Clinical Trials Program, Genitourinary Medical Oncology, The Tisch Cancer Institute at Mount Sinai, Professor, Urology, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates
May 14, 2022 View All Press Releases"Dr. Galsky Discusses Combination Immunotherapy In Bladder Cancer"
Jun 29, 2018 View All Press Releases